In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 38 days of free consultation


Dynamics of left ventricular ejection fraction in patients with stable coronary artery disease after coronary artery bypass grafting

Session Poster Session 2

Speaker Olga Yepanchintseva

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Systolic Ventricular Dysfunction
  • Session type : Poster Session
  • FP Number : P884

Authors : O Yepanchintseva (Kiev,UA), O Zharinov (Kiev,UA), K Mikhaliev (Kiev,UA), B Todurov (Kiev,UA)


O Yepanchintseva1 , O Zharinov2 , K Mikhaliev3 , B Todurov1 , 1Heart Institute of the Ministry of Healthcare of Ukraine - Kiev - Ukraine , 2National Medical Academy of Postgraduate Education - Kiev - Ukraine , 3State Scientific Institution "Scientific and Practical Center of Preventive and Clinical Medicine" - Kiev - Ukraine ,


Purpose: to study clinical characteristics of patients with stable coronary artery disease (CAD) in groups with different dynamics of left ventricular (LV) ejection fraction (EF) after coronary artery bypass grafting (CABG); to assess LV EF dynamics after CABG in groups with different baseline value (grade) of LV EF.

Methods. We conducted a prospective single-center study and enrolled 384 patients with stable CAD, selected for CABG (328 (85,4%) males and 56 (14,6%) females, age 39-92; average age (61±8) years. We analyzed demographic, clinical, laboratory, echocardiographic, coronary angiographic, intra- and postoperative data. The changes of LV EF were evaluated at period 1 (between 6 and 12 months after CABG) and period 2 (24 months after CABG). The total sample of enrolled patients were subdivided retrospectively into three groups according to the LV EF change: 1) 1st – LV EF relative change of =10% towards its improvement (n=110 [28,7%]); 2) 2nd – "without change" (LV EF relative change up to 10% in both directions; n=207 (53,9%); 3) 3rd – LV EF relative change of =10% towards its decline (n=67 [17,4%]). LV EF at both follow-up periods was assessed in 128 (33,3%) patients. The sample of 128 patients was used for LV EF change evaluation depending on baseline LV EF grade: LV EF =50% (n=35; 27,3%); LV EF 40-49% (n=27; 21,1%) and LV EF <40% (n=66; 51,6%). Numeric data were presented as median with interquartile range.

Results. Group 3, compared to the pooled group 1 and 2, was characterized by the higher frequency of patients with HF stage C2 (modified AHA/ACC classification, 2007): 20/67 (18,2%) vs. 10/274 (3,6%), respectively (??0,001). The baseline LV EF in group 1 was significantly lower compared to that in groups 2 and 3: 37% (32-47%), 55% (45-62%) and 52% (38-59%), respectively (??0,001 for both comparisons). The frequency of patients with preserved LV EF (=50%) was lower in group 2, as opposed to groups 2 and 3. Group 3, in contrast to groups 1 and 2, was characterized by the higher value of end-systolic LV volume (and its index), as well as the higher frequency of patients with mitral and tricuspidal regurgitation. At period 1, the structure of the sample of 128 patients by LV EF grades was as follows: LV EF =50%, 40-49% and <40%, respectively, 54 (42,2%) patients, 38 (29,7%) and 36 (28,1%). At period 2 we observed the shift towards increased frequency of patients with  LV EF <40% (55 (43,0%) patients).

Conclusions. The LV EF improvement at different follow-up periods was associated with worse baseline LV EF and more prevalent HF stage C2 cases. The LV EF dynamics in patients with baseline LV EF <50% was "biphasic": the initial LV EF improvement or recovery was subsequently shifted to its decline in part of the patients. The determination of predictors of different LV EF dynamics patterns is crucially important for individualized management of post-CABG patients.

This content is currently on FREE ACCESS, enjoy another 38 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are